Ipsen Sa
Material Topics
Sustainability statement, in full
The complete text of Ipsen Sa’s FY2025 sustainability statement is held here – 246 pages, captured from the published report. Every disclosure below also links to its own passage.
Value chain diagram – from the 2025 report (click to enlarge)
ESRS 2 – General Disclosures
GOV-1The role of the administrative, management and supervisory bodiesReported
The role of the administrative, management and supervisory bodies
Reference: pages 187-190.
The Board of Directors has 14 members (1 executive, 13 non-executive), eight of them non-French, and two employees elected by the French and European works councils sit on it (page 187). Its committees are the Audit, Nomination, Compensation, Ethics, Governance and CSR, and Innovation and Development Committees. The Executive Leadership Team (ELT) has 14 members, seven women and seven men (page 187).
Board gender split is 42% female and 58% male; 36.36% of Board members are independent in 2025 (33.33% in 2024) (page 188).
Sustainability oversight (page 189): the Board "Defines multi-year CSR strategy including Climate" and validates sustainability policies and reports; the Ethics, Governance & CSR Committee oversees the Group's CSR strategy, ethics and compliance; the Audit Committee controls the quality of extra-financial information; the Compensation Committee integrates CSR criteria into executive pay; a Sustainability Strategic Committee and the Sustainability Department coordinate deployment.
On expertise, the report states that subject matter experts in the double materiality exercise are selected for their functions and knowledge of stakeholder expectations, and describes the Board's collective expertise in business ethics, governance and social responsibility (page 190).
GOV-2Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodiesReported
Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodies
Reference: page 191.
"At least twice a year, the Sustainability team presents an update on Sustainability Strategy implementation to the Ethics, Governance and CSR Committee including results and effectiveness of policies, actions, metrics and targets." Risk Management presents an annual update of the Group Risk Map, which includes macro sustainability risks, to the Audit Committee. Global Internal Audit presents internal audit findings, including on Business Ethics topics, to the Audit Committee at least five times a year (page 191).
The Audit Committee received an update on the impacts, risks and opportunities reviewed in the 2025 double materiality assessment and notes that "the materiality remains focused on the same matters as in the previous assessment". Ipsen's Sustainability Strategy is reviewed annually against the double materiality outcome, and CSR criteria sit within the impact scale of the risk framework (page 191).
GOV-2(was GOV-3)Integration of sustainability-related performance in incentive schemesReported
Integration of sustainability-related performance in incentive schemes
Reference: page 192.
A CSR criterion is included in the CEO's annual variable compensation and, from 2025, becomes a criterion in its own right alongside the financial criteria (page 192; detail in section 5.4.1.3 of the document).
Long-term incentives for Executive Corporate Officers and certain managing executives carry CSR criteria (page 192):
- LTI 2024-2026: Environment, reduction of GHG emissions for scope 1, 2 and part of scope 3; Access to Healthcare, acceleration of regulatory submission for selected underserved markets.
- LTI 2025-2027: Environment, share of spend of top suppliers having GHG commitments equivalent to Ipsen's; Social, increase of the internal pipeline to fuel leadership positions.
Completion of the annual ethics e-learning is also linked to short-term incentives (page 348).
GOV-3(was GOV-4)Statement on due diligenceReported
Statement on due diligence
Reference: page 193.
Section 4.1.3.1 maps the core elements of due diligence to the chapters of the statement: (a) embedding due diligence in governance, strategy and business model (sections 4.1.2.2 and 4.1.4.3); (b) engaging with affected stakeholders (section 4.1.6 and the topical chapters on own workforce, product quality and patient safety); (c) identifying and assessing adverse impacts (sections 4.1.5 and 4.1.7 and the topical IRO tables); (d) taking actions (transition plan, climate, own workforce, healthcare and anti-corruption policies and actions); and (e) tracking effectiveness (climate performance, own workforce, healthcare and corruption targets and metrics) (page 193).
The disclosure is a cross-reference table rather than a narrative statement; the substance sits in the chapters it points to.
GOV-4(was GOV-5)Risk management and internal controls over sustainability reportingReported
Risk management and internal controls over sustainability reporting
Reference: pages 194-195.
Ipsen says the second reporting year "has shifted its focus toward consolidating and stabilizing the core elements of our sustainability reporting framework", after a first-year programme that set up governance, cross-functional teams and the initial double materiality assessment (page 194). Processes were reviewed, updated and documented, with experts accountable for their section, disclosure and data accuracy.
Improvements named for 2025 include the appointment of an ESG Reporting Lead, increased external benchmarking, additional external stakeholder input, reformulation of impacts, risks and opportunities, topic-specific external consultancy review (for example the CO2 footprint) and year n-1 comparisons for newer datapoints (page 195). The Audit Committee and the Ethics, Governance and CSR Committee are regularly informed of key challenges and actions (page 195).
SBM-1Strategy, business model and value chainReported
Strategy, business model and value chain
Reference: pages 195-202.
Ipsen is a global biopharmaceutical group focused on innovation and Specialty Care, with three therapeutic areas: Oncology (69.2% of sales), Neuroscience (20.3%) and Rare Disease (10.5%). It sells more than 9 drugs in more than 100 countries, with a direct commercial presence in 38 countries (page 195). Total revenue is EUR 3,929.2 million (2024: EUR 3,574.5 million) and headcount 5,535 (page 196); the same page gives sales by area of Europe 39.8%, North America 35.1% and rest of the world 25.1%.
Sustainability goals are set and reported at Group level across four pillars, Healthcare, Environment, People and Governance (page 196). The value chain is mapped as upstream (sourced materials, CROs, partnerships, CMOs), own operations (manufacturing, development, sales, regulatory) and downstream (distribution, patients, HCPs and hospitals, regulators and payers) (page 200), with a description of product types and raw material origin for each therapeutic area (page 201).
SBM-2Interests and views of stakeholdersReported
Interests and views of stakeholders
Reference: pages 208-210.
Ipsen names its key stakeholders as patients and patient advocacy groups, employees, healthcare professionals and organisations, scientific communities, business partners and suppliers, communities and civil society, legislators and regulators, industry representatives, and investors and rating agencies, and includes "silent stakeholders such as nature" (page 208). A table sets out for each group the engagement method, the purpose of engagement and how the Board is informed (pages 209-210).
Examples: in 2024 Ipsen ran its third global patient organization engagement survey, with 85 organizations responding and a satisfaction score of 8.7/10; employee views come from the annual Engagement Survey, with six sustainability-related themes, and the CHRO presents an annual summary to the Board; views of regulators and industry groups reach the Board through the Ethics, Governance and CSR Committee (pages 209-210).
SBM-3Material impacts, risks and opportunities and their interaction with strategy and business modelReported
Material impacts, risks and opportunities and their interaction with strategy and business model
Reference: pages 211-219.
The 2025 double materiality assessment keeps the same material matters as the prior year, renamed or regrouped (page 211). Material matters are Climate change adaptation and mitigation (E1), Health, safety and well-being, Talent retention and attraction, and Diversity, equity and inclusion (S1), six Healthcare matters (S4), and Corporate culture and Corruption and bribery (G1) (pages 184-185, 211). The IRO table gives type, time horizon and position in the value chain for each (pages 213-216).
Changes in 2025: a risk on "Market access and availability of Ipsen's medicines" was removed and the "Cost savings" opportunity was reclassified as not material; counterfeit-product impact and risk became material (pages 212-213, 400).
On financial effects, Ipsen "identified no significant impact of material risks and opportunities on its financial position, performance, or cash flows for the reporting year", and applies the phase-in provision for anticipated financial effects (page 219).
Climate-specific resilience content is also presented under E1-3 (2025 ESRS numbering).
IRO-1Description of the processes to identify and assess material impacts, risks and opportunitiesReported
Description of the processes to identify and assess material impacts, risks and opportunities
Reference: pages 202-207; pages 217-218 for pollution, water, biodiversity and circular economy.
Ipsen ran its inaugural double materiality assessment in 2024, grouping impacts, risks and opportunities into 28 matters across the value chain using benchmarks, external sources, the SASB Materiality Finder Tool and internal expert interviews (pages 202-203). In 2025 the assessment was reviewed annually, with a full reassessment every three years or on significant change, wider external input (a low-carbon consulting firm, insurers, a patient organization survey), and scoring aligned to the Enterprise Risk Management framework (page 204).
Impacts are scored on severity (scale, scope, irremediability) and likelihood; "The materiality threshold has been set at >2 and materiality was assessed gross" (page 205). Financial materiality uses the same ERM impact and likelihood scales (page 206). Outcomes feed the annual Group Risk Map and the Audit Committee (page 206), and opportunities are identified through HR, healthcare, governance and ISO 14001 environmental management routes (page 207).
Specific text for pollution, water, biodiversity and circular economy explains why each was found not material (pages 217-218).
Climate-specific risk identification and scenario analysis is also presented under E1-2 (2025 ESRS numbering).
IRO-2Disclosure requirements in ESRS covered by the undertaking's sustainability statementReported
Disclosure requirements in ESRS covered by the undertaking's sustainability statement
Reference: page 219; pages 355-362 (Appendix B); pages 362-398 (Appendix C).
Section 4.1.8 points to two annexes. Appendix C, "Disclosed ESRS Data Points and Their Location in the Sustainability Statement", is a datapoint-level index listing ESRS, disclosure requirement, paragraph, name and the section where each is located (page 362 onward). It covers ESRS 2 (BP-1, BP-2, GOV-1 to GOV-5, SBM-1 to SBM-3, IRO-1, IRO-2) and, among the topical standards, E1 (E1-1 to E1-9), S1 (S1-1 to S1-6 and S1-8 to S1-17), S4 (S4-1 to S4-5) and G1 (G1-1, G1-3, G1-4). For E2 to E5 it lists only the topic-level IRO-1 datapoints, located in section 4.1.7.
Appendix B lists datapoints derived from other EU legislation with their location, and marks many topical datapoints as "Not material to Ipsen", including those for E2 to E5, S2 and S3 (pages 358-361).
The topical standards the statement treats as material are E1, S1, S4 and G1 (page 217). Ipsen states that it "has identified entity-specific disclosures related to the Healthcare pillar" (page 219).
E1 – Climate Change
E1-1Transition plan for climate change mitigationReported
Transition plan for climate change mitigation
Reference: pages 228-231.
Ipsen has a climate transition plan, presented to and approved by the Board as part of the complete Sustainability Statement (page 228). SBTi validated updated targets in July 2025 (page 243): -57% absolute scope 1 and 2 and -28% absolute scope 3 by 2030 against a 2019 baseline, and science-based net-zero by 2045 with at least a 90% reduction across scopes 1, 2 and 3, residual emissions balanced by carbon removals (page 228). By 2025 Ipsen reports a 54% reduction in scope 1 and 2 (market-based) and a 16% reduction in scope 3 against 2019 (page 228).
Levers are tabulated with scope, timeframe, maturity and external dependency (electrification of heat, electric vehicles, heat recovery, green electricity, real estate footprint, F-gas leak reduction, biofuel for generators; for scope 3, supplier engagement, packaging, waste, air travel, logistics) with waterfall charts to 2030 (pages 229-231). Locked-in emissions from natural gas heating, distribution logistics and steam generation have specific pathways (page 228). Ipsen states it "is not excluded from Paris Agreement benchmarks" (page 228) and that the plan is integrated in the ERM framework and budgeting cycles (page 228). The report says OpEx for the plan cannot yet be estimated reliably (page 236).
E1-2(was covered under ESRS 2 IRO-1)Identification of climate-related risks and scenario analysisReported
Identification of climate-related risks and scenario analysis
Back-filled from ESRS 2 IRO-1 and the E1 climate section, where this content is disclosed in the FY2025 report (pages 225-226 and 242). This disclosure requirement did not exist under the 2023 ESRS the report was prepared against.
Physical risk (page 225): In 2025 Ipsen updated its physical climate risk analysis with Carbone 4, a gross screening of 330 sites (54 Ipsen-owned and 100 insured external sites), covering own operations and insured external storage and 14 hazards across temperature, water, wind and solid mass. Time horizons are current/historical (1995-2014 reference), 2030 and 2050. For medium and long term it used SSP2-4.5 and SSP5-8.5; coastal flooding used WRI 2085 data and wind hazards regional IPCC projections at a 2°C warming level. The assessment is gross, ignores existing mitigation and does not quantify financial impacts (pages 226-227).
Transition risk (page 226 and 242): the report lists IPCC pathways limiting warming to 1.5°C and 2°C, SSP2-4.5, SSP5-8.5 and the IEA Net Zero Emissions by 2050 scenario as scenarios it draws on for strategic planning, and describes assets and activities incompatible with a climate-neutral economy (business travel, steam generation from natural gas, fleet).
No global average temperature projection per scenario is stated, and the report does not say which scenario was used for which transition analysis; "While Ipsen does not rely on a single deterministic scenario" (page 240).
E1-3(was covered under ESRS 2 SBM-3)Resilience in relation to climate changeReported
Resilience in relation to climate change
Back-filled from ESRS 2 SBM-3 and the E1 climate section, where this content is disclosed in the FY2025 report (pages 220, 225-227). This disclosure requirement did not exist under the 2023 ESRS the report was prepared against.
Ipsen states it "completed a comprehensive climate-resilience assessment across its operations" covering physical and transition risks and opportunities across manufacturing, R&D, commercial activities and suppliers (page 220). The results are given at portfolio level: under the 2050 horizon and SSP5-8.5, most sites are exposed to at least one hazard generating high gross risk, with higher exposure in the Mediterranean basin and the Americas, and heat stress and pluvial flooding the most frequent hazards (page 226).
The report adds that the results "did not indicate critical risk concentrations requiring immediate financial adjustments at this stage" and that the analysis did not quantify financial impacts; scope and depth are to be expanded, including site-specific vulnerability, mitigation measures and value chain coverage (pages 226-227). Implications are drawn for cooling demand, energy resilience and HVAC systems (page 226), and results feed site-level assessments under ERM and resilience planning (page 226).
E1-4(was E1-2)Policies related to climate change mitigation and adaptationReported
Policies related to climate change mitigation and adaptation
Reference: pages 231-232.
Ipsen states it has "a structured and comprehensive framework of policies" for climate mitigation, adaptation, energy management and sustainable mobility (page 231). Policies named: the Natural Resources Preservation (NRP) Program (all manufacturing, R&D and significant office locations; accountable executive is the Executive Vice President Technical Operations), the Travel Policy, the Global Car Policy (70% battery electric vehicles by 2030), the Sustainable Procurement Ambition (strategic and key suppliers), and the Enterprise Risk Management Policy for adaptation (page 232).
A table gives for each policy its key content, scope, most senior accountable role, third-party standards respected (for example SBTi standard, GHG Protocol, ISO 14001, ISO 50001, Paris Agreement) and how it is communicated (page 232). Governance sits with the NRP Steering Committee, Enterprise Risk Committee, ELT and Audit Committee (page 231).
E1-5(was E1-3)Actions and resources in relation to climate change policiesReported
Actions and resources in relation to climate change policies
Reference: pages 233-239.
A table of key actions covers enterprise risk management and business continuity plans, the NRP programme (target of -57% scope 1 and 2 and -28% scope 3 by 2030; progress -54% and -16%; 100% renewable electricity), travel policy, fleet transition (55% of fleet on battery electric vehicles achieved, 57% fleet emissions reduction 2022-2025) and supplier engagement, each with scope, horizon, progress and resources (page 233). Scope 1 and 2 and scope 3 roadmaps follow (pages 235-238).
Site investments in 2025: Wrexham GBP 275,000 (about EUR 320,000), Signes EUR 74,000 and Dublin EUR 630,000 (pages 236-237). The report says the company "is not in a position to publish a consolidated and reliable estimate of OpEx directly attributable to the transition plan" (page 236). Actions in 2025 are estimated to have contributed about 30,000 tCO2e of reduction against 2019 (page 239). The supplier carbon KPI moved from 62% (2024 baseline) to 77% of top-supplier spend aligned (page 239). Financial resources are described as embedded in operational budgets (page 233), with CapEx and OpEx linked to the EU Taxonomy report (page 239).
E1-6(was E1-4)Targets related to climate change mitigation and adaptationReported
Targets related to climate change mitigation and adaptation
Reference: pages 240-245.
Near-term targets validated by SBTi: -57% absolute scope 1 and 2 (market-based) and -28% absolute scope 3 by 2030 against 2019, and net zero by 2045 including a 90% reduction across scopes 1, 2 and 3 (page 243). 2019 baseline values are scope 1 14,316 tCO2e, scope 2 market-based 4,343, scope 3 121,718 and total 140,377 tCO2e (page 244). The table on page 243 shows 2030 absolute values of 8,023 tCO2e for scope 1 and 2 and 87,591 tCO2e for scope 3; no intensity or location-based targets are set.
Ipsen "does not set annual year-over-year greenhouse gas reduction targets" (page 243). The baseline was re-based in 2024 after a scope 3 methodology review, and targets were resubmitted (pages 244-245). Methodologies are the GHG Protocol, SBTi Corporate Net-Zero Standard and ISO 14064, with stated assumptions on growth, efficiency, F-gas, fleet electrification, renewable electricity and supplier decarbonization maturity (pages 244-245). Progress is monitored monthly and quarterly (page 244).
E1-7(was E1-5)Energy consumption and mixReported
Energy consumption and mix
Reference: pages 246-247.
Total energy consumption fell to 77,404 MWh in 2025 from 87,165 MWh in 2024 (-11.2%) (page 246). Fossil energy was 36,655 MWh (2024: 45,447), a 47% share (2024: 52%); fuel oil fell 36% to 9,846 MWh and natural gas 11% to 26,809 MWh. Renewable energy was 41,709 MWh, 53% of the mix (2024: 48%), including 164.9 MWh of renewable fuel (HVO at the Dublin site) and 280 MWh of self-generated solar (page 247). The 2024 nuclear share (9 MWh) was eliminated in 2025 (page 246).
All net revenue (EUR 3,929.2 million) comes from high climate-impact sectors (NACE Section C, Division 21), giving an energy intensity of 19.7 MWh per EUR million, down from 24.4 (page 247).
E1-8(was E1-6)Gross Scopes 1, 2, 3 and Total GHG emissionsReported
Gross Scopes 1, 2, 3 and Total GHG emissions
Reference: pages 248-262.
2025 emissions (page 257): scope 1 8,638 tCO2e (2024: 9,932); scope 2 location-based 5,899 and market-based 0 (2024: 289); scope 3 101,734 tCO2e (2024: 90,705, +12%; 2019 base year 121,718). Total GHG is 116,061 tCO2e location-based and 110,372 market-based (page 259). Scope 1 and 2 market-based is 8,638 tCO2e, 15% below 2024 and 54% below 2019 (page 258).
Largest scope 3 categories: purchased goods and services 64,216 tCO2e, capital goods 9,702, upstream transportation 6,801 and business travel 6,722 (page 257). Scope 3.10, 3.11, 3.13, 3.14 and 3.15 are excluded with reasons (pages 249-250). Fugitive refrigerant emissions rose to 957 tCO2e from 247 following a limited number of significant leak events (page 258). GHG intensity is 28.1 tCO2e per EUR million of net revenue market-based (page 259). 18% of scope 3 is calculated from primary data and scope 2 contractual instruments are detailed (page 262). Methodologies and uncertainty are set out per category (pages 248-256, 352-354).
E1-9(was E1-7)GHG removals and GHG mitigation projects financed through carbon creditsReported
GHG removals and GHG mitigation projects financed through carbon credits
Reference: pages 263-265.
Ipsen "does not undertake GHG-removal or storage activities within its own operations or within its upstream and downstream value chain", so it reports no in-house removals (page 263). It has a public commitment to carbon neutrality for scope 1 and 2 in 2025, to be met by retiring early 2026 8,638 tCO2e of biogenic removal credits from the AMC Maine Woods improved forest management project (ACR standard, 2022 vintage) (pages 263, 265). None of the credits are from reduction projects, from the EU, or qualify as corresponding adjustments (page 265).
Separately Ipsen finances a wider portfolio outside its value chain, including Skyridge Farms (3,500 tCO2e, Verra, reductions) and a historical forestry portfolio (2016-2024), reported separately and not used for the neutrality claim (page 264). Non-permanence and leakage risk management, and the scope of the claim, are described (pages 264-265).
E1-10(was E1-8)Internal carbon pricingReported
Internal carbon pricing
Reference: page 266.
Ipsen has no internal carbon pricing scheme: "While Ipsen has not yet established a formal internal carbon pricing scheme, Ipsen is fully committed to designing and initializing the implementation of a robust and effective framework in the coming years." The report states that "requirements under the E1-8 disclosure criteria are not met, as the internal carbon pricing mechanism is still under development" (page 266). In 2025 Ipsen began preparatory work with Carbone 4 on benchmarking, governance and a roadmap, including testing the resilience of its climate scenario portfolio with carbon pricing. The basis-for-preparation section repeats that the mechanism "remains under assessment" (page 186).
S1 – Own Workforce
S1-1Policies related to own workforceReported
Policies related to own workforce
Reference: pages 280-284; 303-304.
Ipsen lists the policies that manage its material own-workforce impacts, risks and opportunities (page 280): the Code of Conduct, HR Principles, Culture Manifesto, Shingo Guiding Principles, the Alert Management and Disciplinary Policies, data protection policies (Global Data Protection Policy, Data Breach Policy, Security Charter), the Enterprise Risk Management Policy, and the EHS policies, ISO 45001 certification, EHS Risk Assessment and Incident Management. A table gives each policy's key content, scope, most senior accountable role, third-party standards (for example UN Global Compact, ILO standards, ISO 45001, EU Directive 2019/1937) and communication (pages 281-282).
Health and safety principles include "Provide a safe, injury-free workplace" and independently verified ISO 45001:2018 certification (page 283). On discrimination, Ipsen maintains "a zero-tolerance approach to harassment" and describes its DE&I policy base (pages 303-304). At global level there are no policies for specific groups, as all policies cover all employees (page 304).
S1-2(was S1-2 + S1-3)Engagement with own workforce and workers' representatives, existence of channels for own workforce to raise concerns or needs and approaches to remedyReported
Processes for engaging with own workforce and workers' representatives about impacts
Reference: pages 284-287.
Ipsen engages through structured representation and collective bargaining where it applies: among 42 countries, those with structured representation covered 51.5% of the workforce at end December 2025 (page 284). Two employees sit on the 14-member Board and a European Works Council of 8 members, established in 2014, meets annually (page 285). Country arrangements are described for France, Italy, Germany, Spain and others, and a table lists engagement frequency, senior accountable role (the local HR Head) and assessment of effectiveness, mostly "legal requirement" (page 286).
Direct engagement includes quarterly "Ipsen Live" and Global Leadership Team meetings, town halls, and the global Employee Experience Survey run by an independent provider: 85% participation and an engagement score of 77 in 2025 (76 in 2024) (pages 286-287). The CHRO is accountable for the survey (page 289).
Processes to remediate negative impacts and channels for own workforce to raise concerns
Reference: page 288.
Employees can raise concerns with their manager, the HR contact or Business Ethics Officer, or through Whispli, "an independent and anonymous 'Speak Up' line available to all employees"; reports are reviewed, triaged and potentially investigated (page 288). In some countries employee representative bodies can request an independent investigation. The report records no use of the OECD National Contact Points route (page 288).
Protection includes a strict non-retaliation policy, confidentiality, anonymous reporting and a safe environment for raising concerns. Under the Disciplinary Policy introduced at the end of 2024, countries report annually on violations and outcomes to the Chief HR Officer (page 288). Survey results are analysed and action plans set: 4,231 comments were received in the 2025 survey (page 288).
S1-3(was S1-4)Taking action on material impacts on own workforceReported
Taking action on material impacts on own workforce
Reference: pages 287-291 (health, safety and well-being); 299-300 (talent); 305 (DE&I).
Resources: around 190 HR professionals in 25 countries, an EHS function with an EHS contact at each of the 4 industrial sites, and a two-person Enterprise Risk Management team (page 287). Actions in 2025 include merging the French headquarters and R&D sites into a new Paris hub opened in July 2025 (34% of employees changed location between October 2024 and October 2025), four AI workstreams including an AI workforce impact assessment, and the 2024-2026 Global Standards of Care benefits programme (pages 289-290).
Talent actions: launch of the "DevelopMe" programme in May 2025, a Season of Development, global development programmes for managers and pivotal roles, a new learning dashboard and talent acquisition improvements (pages 299-300). DE&I actions include five Employee Resource Groups, four annual awareness events and an annual Demographic Survey sent to 86% of employees in 2025 (page 305).
S1-4(was S1-5)Targets related to own workforceReported
Targets related to own workforce
Reference: pages 275-279 (policy, action and target tables); 291-292; 301; 306.
Targets are set per material matter and classified by the company as metrics, fixed targets, annual targets or progressing targets (page 280). Examples: accident frequency rate annual target 0.61, zero medicalized accidents, zero fatalities and zero declared occupational diseases (pages 275, 291); at least 20 training hours per employee per year and 90% of employees with a development plan (pages 278, 301); employee voluntary turnover target of 10.5% (page 301); gender parity of at least 45% of each gender in the GLT and ELT, and a diversity score of at least 80 (pages 279, 306).
Tables state how each target is set, the source of performance data, the accountable executive and, in a separate table, how the workforce is engaged in target setting (pages 291-292, 294, 301, 306).
S1-5(was S1-6)Characteristics of the undertaking's employeesReported
Characteristics of the undertaking's employees
Reference: pages 293; 295-296; 302; 309.
Headcount was 5,535 at 31 December 2025 (2024: 5,355): 3,399 women and 2,136 men, with none not declared (page 295). 5,402 are permanent and 133 temporary, with no non-guaranteed hours employees (page 295). By region: France 1,553, UK and Ireland 1,089, North America 819, China 403 (page 295). Headcount excludes the CEO, contractors, trainees, apprentices and contingent workers, and uses headcount rather than FTE (FTE is 97.6% of headcount) (pages 293, 295).
754 employees left in 2025 (2024: 829), a turnover rate of 14.3% (16.2% in 2024) (page 302). Age distribution: 9% under 30, 63% between 30 and 50, 28% over 50 (page 309). The acquisition of ImCheck Therapeutics (47 employees) is noted (page 293).
S1-7(was S1-8)Collective bargaining coverage and social dialogueReported
Collective bargaining coverage and social dialogue
Reference: pages 284-286; 297.
36% of total employees are covered by collective bargaining agreements in 2025 (page 297). The S1-8 mandatory table lists coverage bands for the EEA countries with more than 50 employees representing over 10% of the workforce (France, Italy, Spain, Germany, Poland, Sweden) and for non-EEA Brazil, and workplace representation for the EEA countries (page 297). The text, headed "Structured Representation, Collective Bargaining and Social dialog (S1-8)", states that countries with structured representation covered 51.5% of the workforce, and describes works councils, the European Works Council and Board representation (pages 284-285). In 2025 these indicators were extended to 100% of headcount, up from 93% (page 186).
S1-8(was S1-9)Diversity metricsReported
Diversity metrics
Reference: pages 309-310.
Top management (the Global Leadership Team, defined as around 135 leaders) numbered 135 in 2025: 72 women (53.3%) and 63 men (46.7%), against 146 in 2024 (81 women, 65 men) (page 310). The report explains how GLT roles are defined and reviewed yearly by the CHRO and validated by the CEO (page 309). Age distribution of all employees is given: 520 under 30 (9%), 3,483 aged 30 to 50 (63%), 1,532 over 50 (28%) (page 309). Gender is reported for the Board and committees (page 188), and cultural diversity by nationality for the total workforce and management (page 307).
S1-9(was S1-10)Adequate wagesReported
Adequate wages
Reference: page 307.
"Ipsen pays all of its employees worldwide more than the benchmark set by the WageIndicator Foundation." The report presents this as evidence that pay is fair, competitive and consistent with industry norms, and says Ipsen is "dedicated to upholding these standards to promote the financial well-being and security of its staff" (page 307). The disclosure is a statement against a benchmark; no country-by-country table of employees below an adequate wage is provided. Appendix D explains that the 2024 analysis confirmed salaries provide an adequate standard of living, a positive impact, while competition for talent is a risk (page 400).
S1-10(was S1-11)Social protectionReported
Social protection
Reference: page 283.
Ipsen states that "all its countries benefit from social protection schemes aligned with local standards and/or the Group's internal policies", and that employees on permanent or fixed-term contracts are covered against loss of income from sickness, unemployment, occupational injury or acquired disability, accidents at work, maternity and parental leave, and retirement (page 283). Exceptions are listed: health coverage in the UK and Ireland begins after probation; Russia, Colombia, Tunisia, Algeria and Singapore have no dedicated unemployment insurance scheme; adoption leave is not provided under local law in Algeria, Tunisia, China and Taiwan; and parental leave beyond maternity and paternity is not statutory in China, Taiwan, Brazil, Colombia, Mexico and Switzerland. The Global Standards of Care programme works to align schemes across countries (pages 283, 290).
S1-11(was S1-12)Persons with disabilitiesReported
Persons with disabilities
Reference: pages 308-309.
Ipsen does not report the number of employees with disabilities: "Due to legal restrictions under the EU GDPR covering all EU member states and EEA countries, as well as similar principles of personal data protection through national legislation in the countries we operate in outside the EU and EEA, we are unable to report on the number of persons with disabilities within our organization" (page 308). Instead a country table shows whether each of the 42 countries has a legal definition of disability and whether it sets a target share of employees, with a final column headed "% of employees with a disability" that carries a percentage for some countries (for example France 5%, Germany 4%, Italy 7%) and N/A for most (pages 308-309). The Atout Coeur Employee Resource Group supports employees with disabilities (page 305).
S1-12(was S1-13)Training and skills development metricsReported
Training and skills development metrics
Reference: pages 300-301.
Average training hours per employee were 27.0 in 2025 (2024: 28.9), with women at 25.5 hours (2024: 31.8) and men at 27.9 hours (2024: 24.4) (page 300). 97.0% of employees took part in regular performance and career development reviews (97.3% in 2024) (page 300). Targets include at least 20 hours per employee per year and 90% of employees with a development plan, tracked in the iLearn and iPeople systems (page 301). Programmes described include DevelopMe, the Global Development Programs and coaching through a global platform (pages 299-300).
S1-13(was S1-14)Health and safety metricsReported
Health and safety metrics
Reference: pages 296-297.
100% of employees, non-employees and value chain workers on Ipsen sites are covered by the health and safety management system (page 296). There were no work-related fatalities in 2024 or 2025 (page 296). Recordable work-related accidents for employees were 8 in 2025 (2024: 6), with 1 for non-employees and 4 for value chain workers on Ipsen sites (page 296); the rate of recordable accidents for employees was 1.10 (2024: 0.91) (page 296). Days lost to injuries were 251 for employees (2024: 63) (page 296). There were no cases of recordable work-related ill health (page 297). The statement cites ISO 45001 certification of the Group EHS management system (page 283) and a 2025 accident frequency target of 0.61 (page 275).
S1-14(was S1-15)Work-life balance metricsReported
Work-life balance metrics
Reference: page 309.
100% of employees, women and men, are entitled to family-related leave in both years (page 309). Take-up among entitled employees was 8.3% in 2025 (8.5% in 2024): 7.7% of men and 8.7% of women in 2025 (page 309). Ipsen's Global Standards of Care provide paid leave for birth or adoption of at least 10 weeks for primary caregivers and 5 weeks for secondary caregivers, moving toward a unified parental leave, with dedicated leave for personal needs or caregiving planned in the 2024-2026 wave (pages 290-291).
S1-15(was S1-16)Compensation metrics (pay gap and total compensation)Reported
Compensation metrics (pay gap and total compensation)
Reference: pages 306-307.
The gender pay gap is 15.9% in 2025 (2024: 16.3%), with category gaps of 30.2% in Support Functions, 19.8% in Production and Supply, 18.4% in R&D and Medical Affairs and 15.5% in Sales, Marketing and BD (page 307). The remuneration gap ratio between the highest paid individual and the median employee is 56.7 (2024: 52.6) (page 307). The highest-paid individual is the CEO, and the amount is that disclosed in the 2024 universal registration document (page 306). Methodology: data from iPeople for all employees as of 31 October, including base salary and variable pay at target, guaranteed allowances, long-term incentives at 2025 fair value and company cars (page 306). Ipsen monitors gender pay equity with a compa-ratio dashboard and a 2% tolerable gap (page 304).
S1-16(was S1-17)Incidents, complaints and severe human rights impactsReported
Incidents, complaints and severe human rights impacts
Reference: page 310.
In 2025 the table reports 2 incidents of discrimination, including harassment (2024: 1), 8 complaints filed through workforce channels (2024: 1) and 3 complaints filed to National Contact Points (2024: 1) (page 310). The narrative on page 288 says "We have no record of these NCPs being used", which does not agree with the table. Fines, penalties and compensation for social and human rights incidents were EUR 0 in 2025 (EUR 55,594 in 2024), and Ipsen states it incurred no material fines, penalties or damages for violations regarding social and human rights in 2025 (page 310). Under the 2024 global Disciplinary Policy each country HR Head reports alerts, breach types and outcomes annually (page 310). The harassment approach and zero-tolerance statement are on page 304.
S4 – Consumers and End-users
S4-1Policies related to consumers and end-usersReported
Policies related to consumers and end-users
Reference: pages 312-342.
Ipsen calls ESRS S4 "Healthcare system" in its statement and gives policies for each of six material matters (page 187). Examples: the Ipsen Quality Policy, signed by the CEO and the Senior Vice President Global Quality and covering all products and services developed, manufactured, distributed and marketed (page 323); the global pharmacovigilance system with an EU Qualified Person for Pharmacovigilance and a three-tier safety governance (pages 325-326); inventory, shortage and manufacturing resilience policies (page 329); a Falsified Products policy (page 331); the Patient Engagement Policy and its SOP (pages 334-335); the Global Data Privacy Policy and Core Privacy Principles (page 338); the Code of Conduct, HCP interaction directive and Business Partner Code of Conduct (pages 340-341); and the Global Pricing Policy and tiered pricing framework for access (page 342).
The human rights commitment cites the UN Global Compact, the Universal Declaration of Human Rights and ILO conventions (page 340).
S4-2(was S4-2 + S4-3)Engagement with consumers and end-users, existence of channels for consumers and end-users to raise concerns or needs and approaches to remedyReported
Processes for engaging with consumers and end-users about impacts
Reference: pages 334-336; also 209.
Engagement is centred on patients and patient organisations. Ipsen "collaborates with more than 250 patient organizations globally to co-create solutions that reflect real patient needs" (page 334). Global Patient Affairs, led by the VP Global Patient Officer reporting to the Chief Medical Officer, builds long-term relationships and co-creates Patient Experience Data, while Patient Advocacy partners with patient organisations and policymakers; national Patient Engagement leads apply the practices locally (pages 334-335). Early patient advisory boards and insight panels inform trial design, endpoints and protocol feasibility (page 333).
Effectiveness is assessed through a biennial Patient Organization survey (8.3 in 2024; the 2024 global survey described in the stakeholder table gave 8.7/10 from 85 organizations) and targets for patient input in Phase II and III trials (pages 209, 334, 336).
Processes to remediate negative impacts and channels for consumers and end-users to raise concerns
Reference: pages 324; 327-328.
For product quality, Ipsen runs a quality risk management process and a Quality Management review at least once a year that covers product complaints, counterfeits and recalls, with remediation actions such as improvements to the Quality Management System, revised quality objectives, resourcing and audits (pages 324-325). The Quality Systems Evaluation Board addresses significant quality issues (page 324).
For patients, Ipsen operates a pharmacovigilance system that collects safety information from patients, HCPs and health authorities through channels identified on its websites, records it in the Global Safety Database, runs signal detection and reports to authorities (page 327). Training means all employees can identify and pass on safety information within 24 hours (page 327). Data privacy complaints, breaches and rights requests are logged and handled under a Personal Data Breach Policy (page 339). Whistleblower channels for stakeholders are described in sections 4.4.1 and 4.4.2 (page 341).
S4-3(was S4-4)Taking action on material impacts on consumers and end-users, and approaches to managing material risks and pursuing material opportunities related to consumers and end-users, and effectiveness of those actionsReported
Taking action on material impacts on consumers and end-users, and approaches to managing material risks and pursuing material opportunities related to consumers and end-users, and effectiveness of those actions
Reference: pages 312-344.
Actions are described per matter. Examples: pharmacovigilance investment and cross-functional safety review boards, with four types of PV training curricula from 1 January 2025 (pages 316-317, 328); dual sourcing, strategic and safety inventory and business continuity plans for supply resilience (pages 330-331); serialization, anti-tampering packaging, third-party audits and industry collaboration against falsified medicines (pages 331-332); early patient input and Target Value Profiles in R&D (pages 333-334); health literacy and patient support programmes, and Fondation Ipsen's Educate, Advocate, Cure work (pages 335-337); privacy impact assessments and breach response (page 339); ethical promotion and mandatory pre-approval of materials (page 341); and access acceleration, tiered pricing and Early Access and Patient Support Programmes (pages 342-344).
Reported effects include no stock-outs in 2025, a resilience index of 71% at Dublin and Signes and 67% at Wrexham, zero confirmed counterfeit incidents, 1,862 patients enrolled in Early Access Programmes and 34 active Patient Support Programmes across 26 countries (pages 331-332, 343-344).
S4-4(was S4-5)Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunitiesReported
Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities
Reference: pages 312-344 (Targets and Metrics sections by matter); entity-specific disclosures in section 4.3.2.
Targets and indicators are stated for each matter, some fixed and some described as indicators to be defined. Stated targets include zero product recalls (page 315), maintaining a compliant pharmacovigilance system and 100% annual completion of PV training (page 328), a zero stock-out objective and a resilience index above 60% per manufacturing site (page 331), zero confirmed counterfeit incidents and 100% serialization (page 332), about 50% of new Phase II and III trials with patient input within six months rising to 100% within 18 months (page 334), a Patient Medical Education Strategy for 100% of new assets (90% in 2025) (page 336), 95% of employees trained on data privacy (page 339), and a target to cut the time from trial readout to filing by 25% (page 343).
Several access indicators are listed as indicators that "will be reviewed annually" without numeric targets (page 322). Ipsen identifies the Healthcare metrics and targets as entity-specific disclosures (page 217).
G1 – Business Conduct
G1-1Business conduct policies and corporate cultureReported
Business conduct policies and corporate culture
Reference: pages 347-349; 190.
The Ipsen Code of Conduct applies to all employees and Board members; supporting global policies are the Anti-Corruption Policy, Conflict of Interest Policy, Alert Management Policy, and Disciplinary Policy, each with a named owner (page 347). Whistleblowing channels include management, HR, Business Ethics, a dedicated email and the anonymous Whispli platform, in line with EU Directive 2019/1937, the French Sapin II and Waserman laws and HHS-OIG guidelines, with confidentiality, anonymity and non-retaliation as core principles (page 348). Alerts are acknowledged within 7 days and investigated independently; investigators report to the Deputy Chief Business Ethics Officer and biannually to the Ethics Committee of the Board (pages 348, 350).
Mandatory annual e-learning on the Code, anti-corruption and conflict of interest is available in over 10 languages and linked to short-term incentives (page 348). The Board's expertise in business conduct is described on page 190. In 2025, 82% of employees agreed that people at Ipsen behave ethically and compliantly, against a target of 80 (page 349).
G1-2(was G1-2 + G1-3)Actions related to business conductPartly reported
Prevention and detection of corruption and bribery
Reference: pages 349-351.
Ipsen's Anti-Corruption Policy sets "zero tolerance for bribery, corruption, and influence peddling", prohibits facilitation payments and improper gifts, and is supported by a Roles and Responsibilities Matrix developed in 2024 (page 349). An Anti-Corruption Program Operational Committee, established in 2023, meets quarterly and reports to the ELT; the anti-corruption system was certified to ISO 37001 in 2021 and renewed in 2022 and 2023 (page 350).
Training: mandatory annual anti-corruption e-learning for all employees including the Executive team, required for eligibility to short-term incentives, with completion at 99% over three years; the Board is trained on the Code of Conduct on a regular basis, next in 2026 (pages 350-351). Investigations are run independently by the Head of Investigations, who reports to the Deputy Chief Business Ethics Officer and biannually to the Ethics Committee of the Board (page 350). All employees are treated as potentially exposed to corruption risk (page 351).
G1-3(part of MDR-T/GDR-T disclosures)Targets related to business conductReported
Targets related to business conduct
Back-filled from the business conduct chapter, where targets are stated under the topic tables rather than as a numbered disclosure requirement. G1-3 became a standalone DR only in the 2025/2026 ESRS; this statement was prepared under the 2023 ESRS.
Ipsen states targets and indicators for both material business conduct matters (pages 345-346, 349, 351):
- Training completion: over 99% completion of mandatory annual e-learning on the Code of Conduct, anti-corruption and conflict of interest (page 349); the anti-corruption chapter sets a floor of at least 95% (page 351). 99.8% of employees completed the training in 2025 (page 351).
- Employee perception: a score above 80 for "People at Ipsen behave ethically and compliantly"; 82 achieved in 2025 (page 349).
- Alert handling: acknowledge alerts within 7 days and complete follow-up investigations within 3 months (page 349).
- Legal compliance: zero condemnations for breaches of anti-corruption laws; none in 2025 (page 351).
- Zero tolerance for retaliation (page 349).
Targets are reviewed annually (pages 349, 351).
G1-4Incidents of corruption or briberyReported
Incidents of corruption or bribery
Reference: page 351.
"In 2025, Ipsen recorded zero convictions or sanctions for breaches of anti-corruption laws or regulations", presented as reflecting the effectiveness of its compliance and ethics framework (page 351). The stated indicator is to "Maintain zero condemnations for breaches of anti-corruption laws or regulations" (page 351). The report gives no separate figures on confirmed incidents of corruption or bribery, or on actions taken, beyond the zero convictions statement and the description of its alert and investigation process (pages 348-350).